78 results about "Embolic Agent" patented technology

To provide a catheter capable of reducing a risk of closing an unintended blood vessel such as a peripheral blood vessel by leak or dispersion of a high polymer material such as an embolic agent.SOLUTION: A catheter 2 includes: a shaft 3 which is the shaft 3 having one or more expanded lumens 11 for balloon expansion, and a delivery lumen 12 of a high polymer material, and has an opening 4 for communicating the delivery lumen 12 and the outside of the shaft 3; a first balloon 21 which is the first balloon 21 disposed at a distal side from the opening 4, and in which the inside is communicated with one of the one or more expanded lumens 11; and a second balloon 22 which is the second balloon 22 disposed at a proximal side from the opening 4, and in which the inside of the second balloon 22 is communicated with the expanded lumen 11 different from the expanded lumen 11 communicated with the inside of the first balloon 21 of the one or more expanded lumens 11, or the expanded lumen 11 communicated with the inside of the first balloon 21.SELECTED DRAWING: Figure 2

A system for transvascular delivery to an aortic arch of a patient includes an embolic protection device, a connector mechanism, and a catheter or sheath for delivering the embolic protection device to a working zone. The embolic protection device includes a support frame having a distal portion and a proximal portion, and a filter member attached to the support frame and configured for preventing embolic materials from passing there through. At least one of the distal portion and the proximal portion includes a spring section configured for providing a radial force between the support frame and a wall of the aortic arch when in an expanded state. The embolic protection device is pivotable axially but not radially relative to the connector mechanism.

A method and a system for thermally or hyperthermally treating an object. A precipitating hydrophobic injectable liquid (PHIL) embolic agent is prepared and enhanced with a magnetic nanoparticle (NP). A delivery device is advanced to a target area and the PHIL−IONP embolic agent is injected directly at the target area. The PHIL and IONPS are observed in-situ using complementary imaging and an impulse is applied to the target area to generate heat sufficient to thermally ablate or induce hyperthymia at the target area. Additional impulses applied to the target areas at later times generate heat sufficient to ablate or induce hyperthymia at the target.

A catheter is operated to longitudinally compress and radially expand an ePTFE ribbon so as to create an occlusion in a blood vessel, at least inhibiting reflux of liquid embolic when injected through the catheter so as to create a distal flow of the embolic through the vessel. The catheter comprises a smaller inner catheter tube coaxially positioned with a surrounding, larger outer catheter tube. A longitudinally disposed segment of ePTFE may optionally be bonded at or proximal to a tip of the inner catheter at a first end thereof, and a second end of the ePTFE is optionally bonded as well at or proximate to a corresponding tip of the outer catheter. In operation, the distal tip of the inner catheter is placed proximate to a desired treatment location and then withdrawn within the outer catheter, thereby corrugating, or generally crumpling, the ePTFE ribbon creating a "crumple zone" serving to at least partially occlude the blood vessel. A liquid embolic may then be injected through the working lumen of the inner catheter thereafter to achieve a more permanent occlusion of the vessel anomaly being treated, while the crumple zone inhibits reflux of the embolic agent.

The invention provides a nano embolism microsphere based on a magnetocaloric effect and a preparation method and application thereof, and relates to the field of medicines. According to the nano embolization microsphere, mesoporous ferroferric oxide is used as a carrier, and rificiguat and bevacizumab are loaded at the same time. The preparation method has the beneficial effects that the magnetic nano embolism microsphere system is constructed for the first time and is combined with the magnetocaloric effect; according to the invention, the embolism system of the magnetic nano-microsphere loaded rificiguat and bevacizumab is constructed for the first time; compared with an embolism agent for independently embolizing the blood vessel, the nano embolism microsphere disclosed by the invention also plays a role in killing residual tumor cells; compared with an uncontrollable embolism agent, the nano embolism microsphere disclosed by the invention can be used for accelerating drug release in an alternating magnetic field and a slightly acidic environment.

An embolic material blocking catheter includes a handle assembly, an elongated element having a lumen, and a deployable embolic material blocking element. The embolic material blocking catheter is configured to accommodate insertion of a treatment catheter into the lumen to position a treatment device distal to the embolic material blocking element for administering a treatment at a treatment site and / or convey embolic material blocked by the embolic material blocking element for extraction from the patient.

This application provides a premix, kit, and application of a premix for preparing an embolic agent. The premix uses a poloxamer to sodium alginate mass ratio of 9:1 to 20:1, which enables the formation of an injectable solution while maintaining good gel properties, and offers ease of preparation and use.

Vascular filters and deflectors and methods for filtering bodily fluids. A blood filtering assembly can capture embolic material dislodged or generated during an endovascular procedure to inhibit or prevent the material from entering the cerebral vasculature. A blood deflecting assembly can deflect embolic material dislodged or generated during an endovascular procedure to inhibit or prevent the material from entering the cerebral vasculature.

Optical transmission microcatheter devices and methods of endovascular embolization are described herein. A microcatheter device is provided that includes a working lumen and a mechanical protection waveguide. The working lumen has at least one outlet port at a distal end of the working lumen and is configured to provide an intravascular injection of a photoactivated embolic agent (PEA) to a target vessel via the at least one outlet port. The mechanical protection waveguide (MPW) is operatively connected to the working lumen and configured to emit at least one electromagnetic wave via the at least one outlet port for delivery to the target blood vessel.

The invention provides a premixing agent for preparing an embolic agent, a kit and application of the premixing agent. The premix adopts poloxamer and sodium alginate in a mass ratio of 9: 1-20: 1, can form a solution with good injectability in use, keeps good gel performance, and is good in preparation and use convenience.

The invention relates to a self-developing medicine-loadable liquid embolism agent and a preparation method and application thereof, and belongs to the technical field of liquid embolism agents. Acrylic ester compounds and vinyl ester compounds are copolymerized according to a certain proportion and subjected to base catalysis hydrolysis, then an iodine-containing compound developing agent is covalently coupled to a macromolecular chain, and the self-developing medicine-loadable liquid embolism agent is obtained. The prepared liquid embolism agent can be continuously and uniformly self-developed, no negative charge group needs to be additionally introduced, the copolymer subjected to base catalytic hydrolysis can serve as a negative charge carboxylate radical group on a macromolecular chain of the copolymer as a drug carrying group, multiple and a large number of chemotherapeutic drugs can be rapidly loaded, the curing time is short, and the curing time is short. The suppository can be used as a tumor treatment suppository and a chemotherapeutic drug carrying suppository for TACE treatment.

The present invention relates to the technical field of biomedical materials, and particularly to a solid-liquid biphasic embolic agent with a surface cilia structure and a preparation method thereof; it includes a liquid embolic material in the oil phase and Janus cilia microspheres with hydrophilic cilia structures; the Janus cilia microspheres encapsulate the liquid embolic material in the oil phase, and when encapsulating, the hydrophilic cilia structures in the Janus cilia microspheres are exposed outward in the aqueous phase, so that the surface of the solid-liquid biphasic embolic agent has a cilia structure; the cilia structure can improve the interaction force between embolic material particles and between embolic material particles and the blood vessel wall, has excellent viscoelasticity and deformation ability, can reach finer arterial blood vessels, realize efficient embolization of thick and thin arteries, and improve the efficiency of tumor embolization chemotherapy; and the cilia structure is combined with the solid-liquid biphasic system, which not only improves the embolization effect, but also enhances the stability of the embolic agent, prolongs the action time, and optimizes the biocompatibility, and will have broad application prospects.

The invention relates to the technical field of medical instruments, in particular to a controllable release balloon catheter which comprises a micro catheter and an outer sleeve which are coaxially arranged, and the outer sleeve is movably arranged relative to the micro catheter in the axial direction; the catheter seat is connected with the micro catheter and the near end of the outer sleeve, the catheter seat comprises a liquid filling cavity communicated with the near end of the micro catheter and a filling cavity, the filling cavity is communicated with a gap between the outer sleeve and the micro catheter, and a filling balloon communicated with the gap is arranged at the far end of the outer sleeve; the micro-catheter comprises a body section and a disengagement section, the near end of the disengagement section is detachably connected with the far end of the body section, and an inner cavity of the disengagement section is communicated with an inner cavity of the body section to form the micro-catheter; the far end of the outer sleeve and the near end of the releasing section form a releasing structure, and the releasing structure is configured to be that when the outer sleeve moves towards the near end relative to the microcatheter till the releasing section is located on the outer side of the outer sleeve, the body section is separated from the releasing section. The disengagement of the micro-catheter is controllable, blood vessels are not damaged, and the embolic agent is not disengaged.

The present invention relates to the field of medical technology, and discloses an injection device for a protective embolic agent through a blood vessel cavity, comprising a first injection syringe and a second injection syringe, wherein the first injection syringe and the second injection syringe are externally detachably connected to a three-way joint, the interior of the three-way joint is fixedly connected to a connecting ring, the exterior of the connecting ring is detachably connected to a locking ring, the interior of the locking ring is threadedly connected to a connector first, the interior of the connector first is slidably connected to a connector first, the interior of the connector first is detachably connected to a connector second, and the interior of the connecting ring is slidably connected to multiple push rods. In the present invention, the difficulty of maintenance is reduced, and the elastic card plate, sealing ring, and connecting tube in the receiving groove cooperate with each other to form an excellent sealing barrier, effectively preventing leakage of the embolic agent, reducing irritation and adverse reactions to human tissue, and further improving the safety and reliability of treatment.

The invention provides a developing agent which is modified iopamidol, a clinically safe nonionic hydrophilic developing agent iopamidol is subjected to structural modification, a hydrophilic side chain and a connecting arm are introduced, and the iopamidol is introduced into a gelatin degradable microsphere matrix with good biocompatibility in a covalent bonding manner; the degradable non-ionic X-ray developing microsphere with good biocompatibility is formed. Developing microspheres prepared by adopting the developing agent provided by the invention not only keep excellent X-ray developing performance, solve the problems of aggregation tendency and biocompatibility of traditional developing microspheres and realize real-time visual monitoring of an embolism process, but also have degradability and good biological safety, and are not only suitable for permanent embolism treatment, but also suitable for treatment of embolism. The solid developing embolism agent can also be expanded to the fields of temporary embolism, tissue engineering and the like, and the solid developing embolism agent with precise developing and safe degradation performance is provided for minimally invasive interventional therapy of diseases such as tumor intervention and vascular malformation.

The application relates to a composite nanogel and a preparation method and application thereof, in particular to the technical field of biomedical materials. The composite nanogel comprises a nanogel framework and tirapazamine and folic acid loaded on the nanogel framework, wherein raw material components of the nanogel framework comprise a temperature-sensitive monomer and a monomer containing a catechol group. The composite nanogel provided by the application can solve the problems that poor blood vessel adhesion of traditional embolic agents easily leads to embolism recanalization, simple physical embolism is difficult to completely remove hypoxic tumor cells, and existing treatment strategies cannot effectively reverse the immune suppression microenvironment after embolism and activate the systemic anti-tumor immune response.

The present disclosure provides compositions including alginate microspheres capable of self-degradation upon rehydration, the alginate microspheres comprising alginate, alginate lyase, and divalent metal ions. The present disclosure also provides methods of making compositions including alginate microspheres capable of self-degradation upon rehydration, comprising alginate, alginate lyase, and divalent metal ions. The present disclosure also provides methods of inducing an embolism in a subject in thereof, and syringes containing the compositions of the present disclosure for use in the methods thereof.

A detachable tip sheathed balloon microcatheter is provided for delivering an embolic agent to a target location for the embolization of an arteriovenous malformation (AVM). The detachable tip sheathed balloon microcatheter including a balloon microcatheter including a first shaft and an inflatable balloon that is coupled to a distal end portion of the first shaft; and a detachable tip assembly that is configured to be detachably coupled to the first shaft of the balloon microcatheter. The detachable tip assembly includes a protective balloon sheath that is coupled to a proximal end portion of the second shaft, wherein when the detachable tip assembly is coupled to the balloon microcatheter, the protective balloon sheath surrounds at least a portion of the inflatable balloon.

A nanocarbon-iodine calcium alginate microspheres and a preparation method thereof are provided, the nanocarbon is added to the microspheres to enhance an imaging capability of iodine under X-ray, which is a good way to solve a problem that an embolic agent in clinical application cannot be imaged under X-ray. In addition, the preparation method is simple with good stability and safety. It is proved through experiments that the microspheres can be imaged under conventional interventional X-ray examination devices in CT and DSA, it is proved through animal experiments that the microspheres have good X-ray imaging performance and embolization effect.

The present invention belongs to the technical field of medical devices, and specifically relates to an occluder and an occlusion system. The occluder includes a fixing portion, a sealing portion, and a connecting portion connected between the fixing portion and the sealing portion. The occluder also includes a plurality of hollow ablation parts, which are arranged on the fixing portion. The occlusion system includes a medium conveying device that can be detachably connected to the connecting portion. By arranging the ablation part on the fixing portion, while the occluder blocks the mouth of the left atrial appendage, the ablation part cooperates with the refrigerant to freeze the left atrial appendage, so that an isolation zone is formed on the inner wall of the left atrial appendage, thereby blocking the conduction of electrical signals between the left atrial appendage and the left atrium, and realizing electrical isolation between the left atrial appendage and the left atrium. In addition, the ablation part located at the fixing portion can also cooperate with the embolic agent to increase the anchoring ability of the fixing portion. After the embolic agent is injected and expanded, the ablation part presses against the inner wall of the left atrial appendage, further reducing the possibility of the occluder falling off from the anchoring position.

The invention relates to the technical field of embolism agents, in particular to an injectable amphiphilic block copolymer liquid embolism agent, a preparation method of the injectable amphiphilic block copolymer liquid embolism agent and an interventional therapy preparation, and the injectable amphiphilic block copolymer liquid embolism agent comprises an amphiphilic block copolymer, an organic solvent and at least one developable material; the amphiphilic block copolymer comprises a hydrophilic chain segment and a hydrophobic chain segment. The liquid embolism agent obtained by utilizing the amphiphilic block copolymer containing the hydrophilic chain segment and the hydrophobic chain segment, the organic solvent and the developable material can be self-assembled to form a lumen structure with a hydrophilic surface in the embolism process, the viscosity of the embolism agent is reduced by grafting the hydrophilic polymer chain segment, and the curing time is prolonged; therefore, the embolism of the blood vessel at the farther end is realized. The liquid embolism agent has controllable embolism property, the biomechanical property of the liquid embolism agent is relatively softer than that of a hydrophobic polymer, the flexibility is increased, and the liquid embolism agent is more suitable for embolism in blood vessels; and the embolism depth reaches the far-end capillary vessel, so that more branches are embolized.

A vaso-occlusive agent for occluding an aneurysm comprises an embolic fluid configured to occlude the aneurysm, and a plurality of AuPt particles suspended within the embolic fluid. At least one of the AuPt particles has a size that is anywhere from 0.1 micron to 100 microns. Additionally, the least one of the AuPt particles comprises a plurality of pores, where the at least one of the pores has a pore size that is anywhere from 1 nanometer to 10 microns. The AuPt particles in the embolic fluid are 10-50% by weight. The AuPt particles in the embolic fluid comprise a volume magnetic susceptibility from -40 x 10-6 to 40 x 10-6.

The present invention discloses the use of a short-term embolic agent in reducing drug accumulation in the liver, hepatic clearance and / or liver toxicity. The present invention provides the use of a short-term embolic agent in the manufacture of a medical composition for: (a) temporarily embolizing blood vessels supplying the liver; and (b) reducing the accumulation of a drug subsequently or concurrently administered intravenously in the liver. The strategy aims to minimize the exposure of a drug (such as LNP) to the liver by temporarily blocking the blood supply to the liver via the portal vein and / or arteries. The present invention significantly reduces the non-specific accumulation of a drug in the liver by temporarily blocking the portal vein, arterial and / or their branch blood flow, thereby greatly reducing the opportunity for the drug to enter the liver from a hemodynamic root.

The invention provides a medicine injection tool and a medicine injection module, which can reduce the burden of an operator and inhibit the adhesion of a medicine such as a liquid embolic substance to a joint inner cavity. A drug injection tool (1) in which a catheter (2) is connected to the tip side (A) and a drug accommodated in a syringe (31) is supplied from the base end side (B), said catheter (2) being provided with a catheter body (21) having a catheter lumen (21a) and a joint (22) that is joined to the base end side (B) of the catheter body (21) and has a joint lumen (224) that communicates with the catheter lumen (21a), the drug supplied from the syringe (31) is injected into the living body through the catheter lumen (21a) without passing through the adapter lumen (224).

A temperature-stable double-emulsion droplet drug-loaded microsphere, and its preparation method and application. The present invention belongs to the field of biomedicine technology. The purpose of the present invention is to solve the technical problem that current drug-loaded microspheres are difficult to store for a long time and have poor temperature stability. The method of the present invention comprises: dissolving the drug in deionized water to obtain an inner phase, adding PDMS and its curing agent to white oil to obtain an intermediate phase; dissolving Tween 80 in deionized water to obtain an outer phase; then generating double-emulsion droplets using microfluidics technology; and reintroducing the double-emulsion droplets into the outer phase and curing at room temperature to obtain drug-loaded microspheres. The drug-loaded microspheres of the present invention are mixed with a storage solution composed of propylene glycol, gum arabic, and deionized water and then used as an embolic agent. The embolic agent of the present invention has excellent temperature stability, fluidity, embolic properties, and long-term stable storage. It is also highly versatile, and the effective active ingredients can be replaced and adjusted as needed.

The invention relates to the technical field of new material detection, in particular to a medical device for intravascular embolism treatment and a control system thereof.The medical device comprises a miniature pressure sensor, a temperature sensor, a magnetic sensor, an LED lamp, a resistance-type heating piece, a catheter, a display screen, an embolism agent storage tank, an embolism agent conveying pipeline, a carrier, a magnetic field generator, the control system and a spiral CT scanner; the high-precision blood vessel 3D model is constructed through the medical image data, the injection speed and the injection amount of the embolic agent are planned, a reasonable injection scheme of the embolic agent and the complete patient blood vessel 3D model are obtained, embolic agent injection can be conveniently conducted on a patient subsequently, and by accurately controlling the intensity and the direction of the magnetic field, the blood vessel 3D model can be obtained. Real-time and accurate positioning of the position and direction of the catheter in a blood vessel is achieved, and accurate release of an embolic agent is achieved through an embolic agent release system integrating temperature control and light curing functions.

The embolic agent according to the present invention includes as an active ingredient a copolymer of a cationic functional group-containing monomer and an aromatic group-containing monomer, the copolymer having at least a part thereof a structure represented by general formula (I) (in the formula, R11 and R12 are hydrogen atoms or alkyl groups having 1 to 20 carbon atoms which may have a substituent, and satisfy a relational formula: R11=R12; Y11 and Y12 are each independently a single bond or an alkylene group having 1 to 20 carbon atoms; Ar11 is an aromatic hydrocarbon group having 6 to 16 carbon atoms which may have a substituent; X11 is an ammonium group or an amino group; and n11 is an integer of 10 to 1,000.)

The invention relates to composite nanogel as well as a preparation method and application thereof, in particular to the technical field of biomedical materials. The composite nanogel comprises a nanogel skeleton, tirapazamine and folic acid, the tirapazamine and the folic acid are loaded on the nanogel skeleton, and raw material components of the nanogel skeleton comprise a temperature-sensitive monomer and a monomer containing a catechol group. The composite nanogel provided by the invention can solve the problems that a traditional embolism agent is poor in blood vessel adhesion and easy to cause embolism recovery, hypoxia tumor cells are difficult to thoroughly remove by pure physical embolism, and an immunosuppressive microenvironment after embolism cannot be effectively reversed and systemic anti-tumor immune response cannot be activated by an existing treatment strategy.